Bevacizumab Versus Cidofovir for the Treatment of Recurrent Respiratory Papillomatosis: a Randomized, Double-blind, Placebo-controlled Clinical Trial

NCT02555800 Phase 2 UNKNOWN

The aim of this study is to compare the efficacy of intralesional bevacizumab, a monoclonal antibody against vascular endothelial growth factor, versus the antiviral drug cidofovir in patients with recurrent respiratory papillomatosis.

Details

Lead sponsor	Centro de Investigación en. Enfermedades Infecciosas, Mexico
Phase	Phase 2
Status	UNKNOWN
Enrolment	36
Start date	2014-12
Completion	2017-06

Conditions

• Recurrent Respiratory Papillomatosis

Interventions

• Bevacizumab
• Cidofovir
• Placebo

Primary outcomes

• Changes in the annual surgery rate — 12 months
  Changes in the annual surgery rate before and after intervention
• Severity of airway affection measured by the Derkay papilloma severity grading scale — 12 months
  Changes in the Derkay papilloma severity grading scale before and after intervention

Countries

Mexico